Lily Kim is an independent consultant in the San Francisco Bay Area focused on analysis and commercialization strategy for new biological technologies. Recently she was part of the business team driving early stage technology commercialization at the Wyss Institute for Biologically Inspired Engineering at Harvard University. At the Wyss Lily worked with a broad range of technologies including infectious disease diagnostics, a dialysis-like treatment for sepsis, shear-activated nanoparticle drug delivery, a therapeutic cancer vaccine, DNA nanotechnology, protein engineering, biomolecular research tools/instruments, and more. While at the Wyss she helped teams uncover potential commercial applications for their technologies, gather market feedback, understand the competition, plan IP strategy, apply for (and win!) major grant funding, assess license vs. startup decisions, create company partnerships leading to licensing, connect inventors with investors, and take steps down the startup path.
In Boston Lily also founded FluidicMEMS, a resource for the microfluidics commercialization community that brings together academia and industry via an event series and a blog, and is now in its 6th year. She has served on the MIT Enterprise Forum Innovation Series Committee, was selected as one of Mass High Tech’s “Women to Watch” in 2013, and is on the Board of Directors of the Hertz Foundation.
Lily has a Ph.D. in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology and an M.Eng. and S.B. in electrical engineering from MIT. Her technical background is in lab-on-a-chip and microfluidic systems — during her graduate studies Lily was awarded a Hertz Foundation fellowship and developed microfluidic devices for investigating embryonic stem cell biology. She wants to understand how we can accelerate and improve the success rate of early stage life sciences commercialization.